Antibody therapy for drug-resistant Pseudomonas bloodstream infections
Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections
Researchers are creating antibody medicines to fight severe, drug‑resistant Pseudomonas aeruginosa infections, especially bloodstream infections (sepsis).
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | West Virginia University NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project ID | NIH-11145897 on NIH RePORTER |
What this research studies
You would hear that scientists are making a cocktail of antibodies that bind the outer surface (LPS) of Pseudomonas bacteria to block and kill the bugs. They will study how one antibody can directly kill bacteria and how combining several antibodies can cover the common types that cause bloodstream infections. Tests will be done in the lab and in mice and will include multidrug‑resistant Pseudomonas samples collected from patients. The team aims to stop bacterial spread and the excessive immune response that leads to sepsis.
Who could benefit from this research
Good fit: Patients with severe or bloodstream Pseudomonas aeruginosa infections that do not respond to standard antibiotics would be the most likely candidates for this kind of therapy.
Not a fit: People with infections caused by other bacteria, mild Pseudomonas infections controlled by antibiotics, or strains not covered by the antibody cocktail are unlikely to benefit.
Why it matters
Potential benefit: If successful, this could become a new treatment option to save people with life‑threatening, drug‑resistant Pseudomonas sepsis.
How similar studies have performed: Antibody treatments have protected animals and shown limited success in humans against bacterial infections, but an LPS‑targeted cocktail for multidrug‑resistant Pseudomonas is a newer approach mainly at the lab and animal testing stage.
Where this research is happening
Morgantown, United States
- West Virginia University — Morgantown, United States (Active)
Researchers
- Principal investigator: Barbier, Mariette — West Virginia University
- Study coordinator: Barbier, Mariette
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.